Abstract: PD57-07
Sources of Funding: None

Introduction

A recent subset analysis of the Prostate, Lung, Colorectal, and Ovarian cancer (PLCO) study has suggested that Finasteride use was associated with a reduced incidence of bladder cancer (HR=0.634, 95% confidence interval=0.493-0.816; p = 0.0004). We sought to validate this finding in a multiracial population in our tertiary care center. _x000D_

Methods

We identified patients in our institutional database with Benign Prostatic Hyperplasia (BPH) based on International Classification of Diseases (ICD) 9 and 10 codes assigned between 2000 and 2016. From this cohort we then identified patients who were on Finasteride and those that developed bladder cancer. All demographic and clinical variables including age, race, smoking history, finasteride use were collected via an institutional database that prospectively extracts data from electronic medical records (EMR). Finasteride use was based on the documented prescriptions. Chi-square test was used to compare the proportion of bladder cancer patients between two groups (i.e. users and non-users of Finasteride). Multivariate logistic regression analysis was performed to determine the association of finasteride use and diagnosis of bladder cancer controlling for age, smoking history and race._x000D_

Results

We identified 42,774 patients with BPH. The median follow-up was 87 months. There were 11,864 (27.7%) African Americans (AA), 11,863 (27.7%) Caucasians, and 6,340 (14.8%) Hispanics in this population. 5,698 (13.3%) patients were prescribed Finasteride. Bladder cancer was diagnosed in 84 of 5,698 (1.5%) patients who were prescribed Finasteride compared with 863 of 37,076 (2.3%), who were not prescribed Finasteride (p<0.001). Multivariate logistic regression analysis showed that Finasteride use was protective of bladder cancer (OR: 0.57, CI: 0.45-0.71, p<0.001). When we stratified the data based on race, Finasteride use was protective of bladder cancer in Caucasians (2.1% vs. 3.8%, p=0.001) and Hispanics (0.8% vs. 1.6%, p=0.042), but not in AA (1.7% vs. 1.7%, p=0.854)._x000D_

Conclusions

Our study confirms previous findings from the PLCO study that men who are on Finasteride have lower incidence of bladder cancer but only in Caucasians and Hispanics. Future research and randomized controlled studies may be needed to confirm these findings. _x000D_

Funding

None